SQI Diagnostics Inc. announced it has successfully converted a multi-biomarker cardiac event prediction test from a pioneer in the field of predictive diagnostic medicine, into an SQI-based multiplex test. The test has also been successfully automated on SQI’s “sample-to-answer” sqidlite™ system.
SQI is a life sciences and diagnostics company that develops and commercializes proprietary multiplexing technologies and products for advanced microarray diagnostics.
Based on the successful completion of product development and test automation by SQI, the customer has acquired a sqidlite for their CLIA laboratory in Irvine, California. This sqidlite system will be installed and undergo final validation in this customer’s CLIA laboratory in December 2017 where they are already servicing thousands of patients from North America annually. The predictive cardiac tests will also be available to their global customer base of renowned cardiologists, hospitals, and reference laboratories around the world.
“We are pleased to be advancing the relationship with this innovative cardiac testing pioneer to the commercial stage,” said Andrew Morris, CEO of SQI Diagnostics. “We believe the revenue potential for kits sales of this product is very promising and we look forward to working with this world-class predictive health innovator to service their large and growing list of customers using this important predictive diagnostic tool in their clinics.”
About SQI Diagnostics
SQI Diagnostics is the life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics. The Company’s proprietary microarray tests and fully-automated systems are designed to simplify protein and antibody testing workflow, increase throughput, reduce costs and provide excellent data quality.
For more information, please visit www.sqidiagnostics.com
Sales and Marketing Contact:
Global Commercial Operations
SQI Investor Relations Contact:
Chief Executive Officer
416.674.9500 ext. 229
Finance and Administration
416.674.9500 ext. 277